- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Expanded indications offer successful outcomes for many more patients
With the FDA's recent approval of expanded indications for Alcon's LADARVision system, I can now treat up to 93% of my myopic LASIK candidates with a customized wavefront-guided procedure.
The current indications are for the correction of myopia up to -8 D, with or without astigmatism up to -4 D, the broadest treatment range for any wavefront-guided system that I am familiar with.
Using this method, the laser treats exactly at the same area where the measurements were obtained, regardless of unavoidable cyclotorsion, allowing the most precise treatment. I also think the fact that we no longer need to be concerned about angle kappa considerations is very important.
Preoperatively, the mean spherical equivalent was -4.10 D (-0.88 to -10.63 D). Mean sphere was -3.57 D, and went as high as -9.75 D. Mean cylinder was -1.07 D, but ranged as high as -5 D.
